Investigational drug · Phase 3
Duanorubicin
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Newly Diagnosed FLT3 Mutated AML.
Phase 3Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "Duanorubicin"
First trial start
2018
Aug 15, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Duanorubicin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Newly Diagnosed FLT3 Mutated AML
Largest trials
Live from ClinicalTrials.gov: studies naming "Duanorubicin" as an intervention, largest first.
- Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AMLPivotal-lookingCompleted
Arog Pharmaceuticals, Inc.Industry
NCT03258931 · 214 participants · Start Aug 15, 2018 · Primary completion Apr 6, 2026
Drug: Crenolanib; Midostaurin and 2 more · For: Newly Diagnosed FLT3 Mutated AML
Sites: Duarte, California; Los Angeles, California; Sacramento, California · 31 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Anthracycline-induced cardiomyopathy.
Keefe DL · Semin Oncol 2001
- Simultaneous determination of free and bound adriamycin, adriamycinol, adriamycinone and duanorubicin in plasma using column-switching technique and protein-coated pre-columns.
Emara S, Morita I, Tamura K, et al. · Talanta 1994
- Mitoxantrone for refractory and relapsed acute leukemia.
Bezwoda WR, Bernasconi C, Hutchinson RM, et al. · Cancer 1990
- Alteration of chromatin structure induced by the binding of adriamycin, daunorubicin and ethidium bromide.
Grimmond HE, Beerman T · Biochem Pharmacol 1982
- Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex.
Andersson B, Andersson I, Beran M, et al. · Cancer Chemother Pharmacol 1979
- Acute monoblastic leukemia: diagnosis and treatment of ten cases.
McKenna RW, Bloomfield CD, Dick F, et al. · Blood 1975
Also in development for Newly Diagnosed FLT3 Mutated AML
- CrenolanibPhase 32 trials
Arog Pharmaceuticals, Inc. · Newly Diagnosed FLT3 Mutated AML, Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.